Oncologic Risk of Rectal Preservation Against Medical Advice After Chemoradiotherapy for Rectal Cancer
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Apr 19, 2019
Trial Information
Current as of May 04, 2025
Completed
Keywords
ClinConnect Summary
The investigators identified patients whose organ were preserved by non-operative management or local excision after neoadjuvant chemoradiotherapy for mid to low rectal cancer. Then, the patients were categorized into two groups according to the agreement on omitting radical surgery (rectal preservation). When treatment decision was agreed by their surgeon, the patients were categorized as intended rectal preservation. When there was disagreement by surgeon on rectal preservation, then the patients categorized as unintended rectal preservation. Oncologic outcome was compared between two gro...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • biopsy proven rectal cancer (anal verge ≤ 10cm)
- • neoadjuvant radiotherapy or chemoradiotherapy
- • no radical surgery after neoadjuvant therapy
- Exclusion Criteria:
- • other malignant disease
- • other fatel disease
- • incompletion of half of radiotherapy course
- • metastasis on initial presentation
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Goyang Si, Gyeonggi Do, Korea, Republic Of
Seongnam, Gyeonggi, Korea, Republic Of
Patients applied
Trial Officials
Jae-Hwan Oh, Ph.D.
Principal Investigator
National Cancer Center, Korea
Kyu Joo Park, Ph.D.
Principal Investigator
Seoul National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials